Trevi Therapeutics to Present at H.C. Wainwright Global Investment Conference

Christel Deskins

NEW HAVEN, Conn., Sept. 09, 2020 (GLOBE NEWSWIRE) — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will present a Company overview, as well as host virtual investor meetings, […]